Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

“Surprising Gaps” in Ovarian Cancer Research, Report Finds

By Drug Discovery Trends Editor | March 3, 2016

There needs to be a better understanding about ovarian cancer, said a new report from the National Academies of Sciences, Engineering, and Medicine.

Ovarian cancer should not be categorized as a single disease, but instead as a “constellation of different cancers involving the ovary,” according to the report, published Wednesday. Also, ovarian cancer often does not begin in the ovaries.

“While progress has been made in ovarian cancer research over the last few decades, much remains to be learned,” said Jerome F. Strauss, chair of the committee that carried out the study and wrote the report. “The more that is understood about the basic biology of various types of ovarian cancers, such as where they originate in the body, the more rapidly we can move toward advances in prevention, screening, early detection, diagnosis, treatment, and supportive care.”

Ovarian cancer accounts for three percent of cancer diagnoses in women, yet is the fifth-leading cause of cancer-related death. Roughly two-thirds of women are diagnosed when the ovarian cancer is at an advanced stage, making the five-year survival rate less than 46 percent.

The report recommends that research should be prioritized on high-grade serous carcinoma, which are the most common type of ovarian tumor but also have the worst survival rates — accounting for nearly 70 percent of deaths.

The committee also found recent evidence that suggests that many ovarian cancers arise in other tissues besides the ovary, such as the fallopian tubes, which eventually metastasize to the ovary. Researchers do not have a complete understanding of how each subtype of ovarian cancer progresses, and the committee stressed that the medical community should prioritize the disease’s cellular origins and how it develops.

Although the majority of women with ovarian cancer respond well to initial treatments, most experience a cancer recurrence — and recurrent ovarian cancers often become resistant to drug therapies. An improved understanding of the different types of ovarian cancers — and their biomarkers — will mean a better chance of developing targeted therapies, researchers said.


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50